Case Report

Biomedical Research and Therapy

, 3:49

First online:

Open Access This content is freely available online to anyone, anywhere at any time.

Umbilical cord derived stem cell (ModulatistTM) transplantation for severe chronic obstructive pulmonary disease: a report of two cases

  • Phuong Thi-Bich LeAffiliated withStem Cell Unit, Van Hanh Hospital
  • , Tuan Minh DuongAffiliated withStem Cell Unit, Van Hanh Hospital
  • , Ngoc Bich VuAffiliated withLaboratory of Stem Cell Research and Application, University of Science, Vietnam National University
  • , Phuc Van PhamAffiliated withStem Cell Unit, Van Hanh Hospital Email author 



Chronic obstructive pulmonary disease (COPD) is a chronic disease affecting the airway of the respiratory system. COPD cases have rapidly increased in recent years, with the disease becoming the fourth leading cause of death worldwide. Stem cell transplantation is a new approach to treat COPD. In this study we report in two cases the use of transplanted stem cells to treat COPD.


Umbilical cord derived stem cells (ModulatistTM) were used in the study. ModulatistTM was prepared according to previous published studies. Two patients with late stage COPD (stage IV) were transfused with Modulatist at a dose of 106 cells/kg. Patients were evaluated by the COPD assessment test (CAT) score as well as the Modified Medical Research Council Dyspnea Scale (mMRC) score, before and after transplantation (1, 3 and 5 months post transplantation).


Results showed that ModulatistTM transplantation significantly improved sever COPD, especially after 3 months. At that time point, the two patients receiving ModulatistTM showed a significantly improvement, from late-stage of COPD (stage IV) to stage I.


Although these initial results suggest that ModulatistTM transplantation is a promising therapy, more clinical studies in COPD patients are warranted to evaluate efficacy.


COPD chronic obstructive pulmonary disease ModulatistTM umbilical cord derived stem cells CAT mMRC